• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compounds as described having the partial formula <IMAGE> These compounds may have a 5-OH or -OMe group amd at the 25- position an isopropylene group substituted by methyl, ethyl or isopropyl. The compounds may be used in agriculture or medicine as antiparasitics, and may be prepared by culturing certain Streptomyces strains, in particular Streptomyces thermoarchaensis NCIB 12015.
    公开号:SU1738090A3
    申请号:SU853957807
    申请日:1985-09-13
    公开日:1992-05-30
    发明作者:Варри Уорд Джон；Мэри Ноубл Хейэл；Портер Нейл；Алан Флеттон Ричард；Ноубл Дэвид
    申请人:Глэксо Груп Лимитед (Фирма)；
    IPC主号:
    专利说明:

    00
    about
    The invention relates to new antimicrobial compounds and methods for their preparation, and more specifically, the invention relates to antimicrobial compound m which can be obtained by fermentation of organisms of Streptomyces.
    S 54 antibiotics are a group of related compounds of formula I
    he shn nsn
    about
    more specifically of formula II
    he
    SNS n
    The invention extends to compounds having the above formulas, both individually and in combination. For certain areas of use, for example in agriculture, in horticulture or in veterinary medicine, it is more convenient
    17380904
    where RJ is the methyl, ethyl or isopropyl group} Rg, is hydrogen or methyl group
    These six substances of formula III
     denote as factor A (R - izopropil, R - hydrogen), factor B (Rj - methyl, R - methyl), factor C (R (- methyl, R - hydrogen), factor D (Rj - ethyl, - hydrogen , factor E (R is ethyl, R / t. is methyl) and factor F (R is isopropyl, R is methyl.) Factors A and C are particularly preferred.
    Factors B, E, and F are derived from component I, and factors A, C, and D are derived from component II.
    The substances according to the invention have antibiotic activity, for example
    ten
    15
    anthelmintic, in particular, against nematodes, and in particular activity against internal and external parasites.
    The use of S54 Antibiotics without separation into individual components, however, for other uses, for example in humanitarian medicine, it may be preferable to use individual compounds.
    The initially isolated antibiotics S 54 (easily separated by chromatography on silica gel into two components which have, for example, anthelminthic activity and quench the UV fluorescence at 254 nm. Component I is characterized by the value of Rf 0.7 - 0.75, and component II - 0, 39 - 0.46, which was determined by thin layer chromatography on Merck 5735 silica gel 60 plates, eluted with a 3: 1 mixture of chloroform and ethyl acetate. Components I and II, where R. is, respectively, -C1C and H , antibiotics S 5-4 may be additional ADDITIONAL purified form six substances of Formula I, are active antibiotic, anthelmintic e.g., having the general formula III
     he
    sn3 n „
    013517
    HOR
    CH3
    20
    25
    thirty
    anthelmintic, in particular, against nematodes, and in particular activity against internal and external parasites.
    In particular, such substances have been found to be active against para-imitative nematodes, for example, Haemonchus contortus, Ostertagia circumci- neta, Trichostrongylus colubiformis. Dictyocaulus viviparis, Cooperia on-cophera, Ostertagia ostertagi, Nip-postrongylus loraziliensis, and parasizing mites, such as Sarcop-tes sp., Psoroptes sp. Therefore, these substances can be used 35 in the treatment of animals and people affected by internal and / or external parasites.
    In addition, it was found that such substances possess anti-fungicidal activity, for example, against Candida sp. Strains, such as Candida albicans, Candida glabrata, and against yeast, such as Saccharomyces carlsbergensis.
    45 These substances are also active against free-living nematode Caenorhabdisis elegans.
    In addition, it was found that the substances obtained by the proposed 50 method are effective in combating insects, tick-borne and nematode pests in agricultural products, horticulture, forestry, stored products and for general public health. Pests of soil and plant fruits, including cereals (for example, wheat, barley, corn and rice, vegetables (for example, co), fruits (for example, blocks, grapes, and citrus fruits), as well as root crops (for example, sugar beets, potatoes) can be effectively destroyed.
    In particular, the proposed substances are found to be active, for example, against fruit mites and aphids, such as Aphis fabae, Aula-corthum curumClexuin, llyzus persicae, et all, and representatives of the genus Tria-1euroides, nematodes, such as representatives of the genus Aphelencoides , Globo- .dera Heterodera et al., Lepidoptera, such as Heliothis, Plutella, Spopoptera, Calandrin, such as Anthoonos grandis, Sitophilus granarius, mealworms, such as Tribolium castaneum, flies, such as 1-Iusca do - mestica, Richter ants, narrow-winged moles-minerov Pear psylla, Thrips tabaci, cockroaches, such as Blatel-la gernanica, Periplaneta americana, and mosquitoes, such as Aedes aegypti.
    In general, these substances can be applied both to the host (animal or human, or plant, or other vegetation), as well as to the pests themselves or their source. Particularly preferred are factors A, B, C, D), E and F, as indicated above. Substances obtained by the proposed method can be used in the form of various dosage forms for administration by any convenient method in veterinary medicine or medicine.
    Compositions which include the proposed substances can be used for parenteral (including intrathoracic, oral, rectal, topical or implant. When formulating, which must be sterile, such as injection, eye drops and ointments, the active ingredient itself can be prepared antiseptic or sterile, for example, after treatment with gamma radiation or ethylene oxide.
    When used in horticulture or farming, the substances obtained by the proposed method can be included in dry or - liquid type formulations, for example, dust, including dust bases, or concentrates, powders, including soluble or moistened powders, granules, including microgranules or granules. dispersed, tablets, flowables, emulsions, such as diluted emulsions or concentrates
    five
    0
    five
    emulsified, immersion liquids such as immersion liquids for roots or for seeds, seed casings, seed tablets, oil concentrates, oil solutions, injections, such as injections in the stem, aerosols, smokes and.
    Typically, such formulations include a compound in combination with a suitable carrier or diluent. Such carriers may be liquid or solid and are intended to facilitate the use of the substance either by dispersing where it should be applied or to provide a formulation that can be formulated by the consumer as a dispersible preparation. Such formulations are well known and can be obtained by conventional methods, such as, for example, mixing and / or grinding the active component (s) together with a carrier or diluent, for example a solid carrier, solvent or surfactant.
    Solid carriers suitable for use in formulations, such as dusts, granules and powders, can be selected, for example, from natural mineral fillers, such as diatomite, talc, kaolin, montmorillonite, pyrophyllite or attapulgite. Highly dispersed silicic acid or highly dispersed absorbent polymers can be included in the composition. The granular adsorbing carriers used may be porous (such as letter 0, ground brick, sepolont or bentonite) or pure (such as calcite or sand). Suitable pre-granular materials may be used, which may be organic or inorganic, and include dolomite and ground plant residues.
    The solvents used as carriers or diluents are aromatic hydrocarbons, aliphatic hydrocarbons, alcohols and glycols or their ethers, esters, ketones, amides of acids, highly polar solvents,
    optionally epoxidized vegetable oils and water.
    Traditional non-ionic, cationic or anionic surfactants can also be used.
    five
    five
    0
    substances, for example ethoxylated alkylphenols and alcohols, alkaline or alkaline earth metal salts of alkyl benzene sulfonic acids, lignosulfonic acids or polymeric phenol sulfonates, which have good emulsifying, dispersing and / or moisturizing properties, either individually or in combination in a composition x
    In addition, stabilizers, anti-tracking additives, viscosity regulators, binding agents and sticky additives, photo stabilizers, as well as fertilizers, food stimulants or other active substances, substances obtained by the proposed method can be used in the compositions. mixed with other insecticides, acaricides and nematocides.
    In these formulations, the concentration of the active material is usually 0.01 to 99% or more, preferably 0.01 to 40% by weight.
    Industrial products are usually supplied in the form of concentrated compositions, which can be diluted for use to an appropriate concentration of the active material, for example, from 0.001 to 0.0001% by weight.
    In agriculture, horticulture and in veterinary medicine, it may be desirable to use whole fermentation broth (without separating it into components or factors) as a source of active substances. Knife L is convenient to use dried broth containing mycelium, 1) lysed mycelium, live or non-living mycelium, isolated from the broth using liquid-solid separation techniques or evaporation techniques, or using a fermentation broth remaining after the separation of the mycelium. If desired, the mycelium may be pasteurized or, for more preferably, dried, for example, by spray drying or roller drying. The mycelium or broth may be included in compositions comprising, conventional inert carriers, drug media or diluents, as described above.
    On the basis of taxonomic studies, a specific microorganism capable of producing the above mentioned plants is a new species of genus
    five
    five
    0
    five
    0
    $
    Ctreptorayces, which was named Streptomyces thermoarchaensis. A sample of this microorganism isolated from the soil was deposited in the permanent collection of cultures of the National Collections of industrial and marine bacteria (Torrey Research Station, Aberdeen, United Kingdom) and has been assigned PS number 1B 12015.
    The invention also extends to any substances that are capable of being produced by the fermentation of S. thermoarchaensis NC1B 12015 and which are optical isomers of the compounds of the formula I. An organism of the genus Streptomyces is preferably Streptomyces thermoarchaensis NC1B 12015 or its mutant.
    Mutants of S. thermoarchaensis NC1B 12015 can occur spontaneously or be produced in a variety of ways. Such methods include ionizing radiation, chemical methods, such as N-methyl-N-nitro-N-nitrosoguanidine (NTG) treatment, heat treatment, genetic techniques such as recombination, transduction, transformation, lysogenization and lysogenic transformation, and selective methods for spontaneous mutants.
    For example, four mutant strains of S. thermoarchaensis NCI B 12015 were obtained, each strain was deposited in the culture collection of the National Collections of Industrial and Marine Bacteria (Research Station Torrey, Aberdeen, United Kingdom) and assigned the numbers NC1B
    12111, NC1B 12112, HC1B 12113 and NC1B 12114: S. thermoarchaensis NC1B 12111,
    12,112.12113 and 12114. Mutant strains NC1B 12111,
    12112 and 12113 are derived by processing spores of S. thernoarchaensis NGIJ 1201 5 K-methyl-K-nitro-N-nitrosoguanidine and then characterized by a one-step Hollide method.
    The mutant strain NC1B 12114 arose with a spontaneous mutation of S. thermoarchaensis NCI B 12015 and was identified as resistant to streptomycin, since it remained viable after exposure to streptomycin (100 mg / ml) at 28 ° C for 5 days.
    Taxonomic studies show that S.thernoarchaensis NC1B 12015 is a microorganism of the new species, the characteristics of which are described below.
    Pa preferred sporulation media — oatmeal agar, malt-yeast agar, and starch agar with inorganic salts — S.ther moarchaensis NC1B 12015 grows abundantly, producing a stable substrate mycelium and aerial mycelium, which generates spores in open spores in open circuits in open spores and in open mycelium, and in open spores in open spores. lateral branches from the main hyphae. On these media, the reverse pigmentation is yellow-brown, and the sporophores are gray. With a hundredfold magnification, it can be seen that sporophores contain 2-5 turns in a chain with 5-10 spores inside each turn of the helix. On average, sporophores contain 20-50 spores. With an increase of 12,000 in a scanning electron microscope, it can be seen that the spores have smooth walls and an ellipsoid shape of 0.7 x1.4 μm in the widest part of the ellipsoid.
    S.thermoarchaensis Id B 12015 V-llets of a gram-positive organism and is able to grow and form spores at 20-50 ° C.
    Comparison of the above data with the published descriptions in the Bergeev Handbook of Definitive Bacteriology shows that the organism 5.. Rthornoensis NC1B 12015 belongs to the genus SLreptomyces.
    The identification of S. thertnoarchaensis NC1B 12015 at the group-species level is carried out using a computerized identification matrix.
    Below are the results of 41 taxonomic tests for S.thernoarchaensis NCTB 12015:
    Sign Result
    The chain of spores is muttovich - The chain of spores is rigidly connected - The chain of spores of the straight chain - The chain of spores is spiral + Fragmentation of the mycelium - The surface of the spores is smooth + The surface of the spores of wrinkles - The color of spores is gray + The color of spores is red - The color of spores is green - Reverse yellow-brown + Reverse red Orange - Melanin Production o
    five
    0
    five
    0
    five
    0
    Adonitol useUse cellobiose +
    Using D-fructose + Using meso-inositolUsing inulin +
    Use of mannitolUse of raffinose using raminoses +
    Using D-xylose-f Using DL-alpha aminobutyric acidUsing L-histidine + Using L-hydroxy
    prolylinseplenie allantoina +
    Arbutin cleavage xanthine disengagement +
    Pectin release +
    Lecithin splitting Nitrate Reduction +
    Production of hydrogen sulfide + Resistance to sodium azide (0.01% w / v) Resistance to chloride
    sodium (7% w / v) - Phenol resistance
    (0.1% w / v) +
    Growth at 45 ° C + Resistance to neomycin
    (50 µg / ml) - Resistance to rafampicin
    (50 µg / ml) + Antibiosis to Aspergillus
    niger LIV 131+ Antibiosis to Bacillus subtilis PS1B 3610 Antibiosis to Streptomyces
    murinus ISP 5091+
    Iutant strains NCI B 12111,
    12112, 12113 and 12114 all have almost similar to S.thermoarchaensis essential features. but
    NC1B 12111 requires adenine for growth, NC1B 12112 - series, NC1B 12113 - histidine, and NCIB 12114 is resistant to streptomycin.
    Microorganisms capable of producing antibiotics 55 can easily be detected by a convenient small-scale test using Caenorhabditis elegans nematodes, for example, by adding a test sample to the nematode suspension and determining the subsequent effect on the chemical inactivity of the latter.
    Production of S5 antibiotics by fermentation of a suitable organism.
    Streptomyces can be carried out by conventional means, for example, by cultivating the body of Streptomyces in the presence of a source of digestible carbon and mineral salts.
    Sources of digestible carbon, nitrogen and mineral salts can be provided by simple or complex nutrients. Carbon sources can usually include glucose, maltose, starch, glycerin, molasses, dextrin, lactose, sucrose, fructose, carboxylic acids, amino acids, glycerides, alcohols, alkanes, and vegetable oils. In general, carbon sources can be 0.5-10. % by weight of the fermentation medium.
    Nitrogen sources may include soybean flour, locking liquids e grains, soluble distillates, yeast extracts, cotton seed flour, peptones, ground nut flour, malt extract, forage syrup, casein, amino acid mixtures, ammonia (gas or solution), ammonia salts or nitrates. Urea and other amides can also be used. Nitrogen sources may comprise 0.1-10% by weight of the fermentation medium.
    Nutrient mineral salts that can be added to the culture medium include salts capable of releasing sodium, potassium, ammonyl, iron, magnesium, zinc, nickel, cobalt, manganese, vanadium, chromium, calcium, molybdenum copper, boron, phosphorus, sulfate, chlorine and carbonate.
    An anti-foam additive may be present to regulate excess pumping 40 using traditionally, which is added periodically as needed.
    Cultivation of the Streptomyces organism is usually carried out at 20-50 ° C, preferably 25-40 ° C, especially about 34 ° C, and it is desirable that the cultivation take place during aeration and stirring, for example, by agitation and stirring. The medium may be initially inoculated with a small amount of a suspension microorganism suspension. Moreover, to avoid growth retardation, it is possible to prepare the vegetative inoculum of the organism by inoculating a small amount of the culture medium with a spore-forming organism, obtained by
    five
    hetative inoculum can be transferred to a fermentation medium or,. something more preferable to one or several seed stages where further growth occurs before transfer to the main fermentation medium. In general, the fermentation is carried out at a pH of 5.5-8.5, preferably 5.5-7.5.
    Fermentation can be carried out for 2-10 days, for example, about 5 days.
    The separation of material containing antibiotics and any of their components or factors, or the introduction of any of their components or factors, is carried out using conventional isolation and separation techniques. S 541 antibiotics are predominantly contained in the mycelium of cells, but can also be found in fermentation broth. The isolation can be carried out before or after the clarification of the fermentation broth, the choice of isolation technique can vary widely.
    Antibiotics can be isolated and separated using a variety of fractionation techniques, for example, adsorption-elution, precipitation, fractional crystallization and solvent extraction, which can be combined in various ways.
    Solvent extraction, chromatography, and fractional crystallization were found to be most suitable for the isolation and separation of substances obtained by the proposed method.
    After fermentation, the mycelium can
    five
    0
    S
    0
    five
    methods such as filtration or centrifugation. The material can then be extracted from the mycelium with a suitable organic solvent, such as ketone, acetone, methyl ethyl ketone or methyl isobutyl carbonate, a hydrocarbon, such as hexane, a halogenated hydrocarbon, such as chloroform, carbon tetrachloride or methylene chloride, an alcohol, such as methanol or ethanol, or a diol, for example, propane diol-1,2, or an ester, for example methyl acetate or ethyl acetate. If mycelium contains a significant amount of water, it is preferable to use a water-soluble solvent.
    More than one extraction is necessary to achieve optimal recovery. Preferably, the first extraction is carried out using a water-miscible solvent, such as methanol or acetone. Antibiotics can be isolated as a crude extract by removal of the solvent. Solvent extracts i can be extracted themselves after reducing the volume of the solvent, for example, by evaporation. At this stage, it is preferable to use a solvent that is not miscible with water, such as hexane, chloroform, methylene chloride or ethyl acetate, or a mixture of them, and sufficient amount of water is added to achieve a satisfactory distribution of antibiotic compounds. Upon removal of the water-immiscible phase, a material containing antibiotics 54 is obtained. Actinate P B can be isolated by crystallization from a suitable solvent, for example isopropanol.
    Purification and / or separation of the active components and / or factors can be carried out by conventional methods, such as, for example, chromatography (including high performance liquid chromatography) on a suitable carrier, such as silica gel, non-functional macrosett adsorption resin, for example, crosslinked polystyrene. resins such as Amberlite XAD-2, XAD-4 or XAD-1180 (manufactured by Room and Haas, Ltd.), or S112 resin (made by Castall. Ltd.), or, together with an organic solvent, cross-linked dextran, such as Sephadex LH20 ( Burma Pharmacy Yu-Kay.Lt e.), or in the case of high performance liquid chromatography, reversible phase carriers such as grafted hydrocarbon silica gel, for example grafted silica gel. This carrier
    more preferably, packed into the column. In the case of non-functional macroresin resins, such as XAD-1180 or S112, mixtures of organic solvents, such as acetopyryl and water, can be used to elute.
    Typically, a solution of the substances in a suitable solvent is run on silica gel or Sephadex columns after the first reduction in solvent volume. The column can optionally be washed and then eluted with a stretch.
    five
    0
    five
    0
    five
    0
    five
    0
    five
    the lord of a suitable polarity. In the case of hesdex and silica gel, alcohols, such as methanol, hydrocarbons, such as chloroform or methylene chloride, or esters, such as ethyl acetate, can be used as solvents. In addition, combinations of such solvents can be used either without water or with water.
    The course of elution and separation of substances can be monitored using conventional techniques such as chromatography, for example thin layer chromatography and high performance liquid chromatography.
    When chromatographed on silica gel, preferably using an eluent such as chloroform: ethyl acetate, the S541 antibiotics are easily separated into components I and II, and component I is eluted first. Factors B, E and D can then easily be obtained from component I using, for example, high performance liquid chromatography. Similarly, factors A, C and D can easily be separated from component II. Alternatively, factor B can be separated with factors E and F by crystallization from an alcohol, such as methanol or isopropanol. Optionally, mother liquors containing E and G reactors can be further purified, for example, chromatography on silica gel, with factors E and F isolated using high performance liquid chromatography.
    After these factors are obtained, they can be further purified by crystallization, for example, from methanol, isopropanol or methanol / water mixture, and this extends to substances that are in a crystalline state.
    Using a suitable combination of the above methods, the substances obtained according to the proposed method are isolated in the solid state. Moreover, the order in which the above purification steps are carried out, and the choice of these steps for use, can vary widely.
    Thus, Lactor B was obtained as a t crystalline solid having a purity higher than 90%. Similarly, A, C, D, E, and F have purity levels greater than 90%. However, these Lecturers are used with a degree of purity appropriate for their intended use: for medical use a degree of purity of at least 90%, preferably higher than 95% is desirable} for use in veterinary medicine, agriculture or horticulture, sufficient degrees of purity are, for example, 50% or less. .
    The invention is illustrated by examples where the following abbreviations are taken: TLC — thin layer chromatography (using plates made by Merck 5735 with silica gel 60, produced by a 3: 1 mixture of chloroform: ethyl acetate)} HC — chromatography on a column of Merck 7734 with silica gel 60 (column length 200 and diameter 4 cm) eluted with a mixture (3: 1) chloroform: ethyl acetate; KHVR - high performance liquid chromatography / PE petroleum ether (bp 60-80 ° C).
    The mediums L, B and C, which are mentioned in the examples, have the following composition.
    Wednesday L, g / l:
    D-Glucose15,0
    Glycerin15,0
    Soy peptone15,0
    Sodium Chloride 3.0 Calcium carbonate 1.0 Distilled water To 1 liter, the pH is adjusted to a value of 7.0 with an aqueous solution of sodium hydroxide to be autoclaved. Wednesday, g / lg
    D-Tlyukoza2,5
    Malt dextrin M ZOE (Rokuett Co., Ltd. of the United Kingdom) 25.0 Arkaza 50 (British Lrcady Co., Ltd.) Korma treacle
    KGNR04
    12.5 1.5 0.125 1.25
    Calcium carbonate MOP (N-morpholino) - propanesulfonic acid 21.0 Distilled water To 1 liter the pH is adjusted to 6.5 with aqueous 5N. with caustic soda solution before autoclaving. Wednesday, g / l:
    B-Glucose2.5
    Malt dextrin MD ZOE (company Rokuett. Ltd. UK) 25.0 Arkazoy 5012.5
    Beet molasses 1,5, 125
    five
    0
    Calcium carbonate 1,25 Silicone 1520 (firm Dow Corning) 0,625
    Distilled water Up to 1 L of pI is adjusted to 6.5 before sterilization. Example 1. Spores of Streptomyces thermoarchaensis NCI B 12015 are inoculated on beveled agar consisting of the following components, g / l: Yeast extract (Oxoid company L21) 0.5 Malt extract (Oxoid company L39) 30.0 Mycological peptone (yrma Oxoid L40) 5,0 Agar P 3 (firm Oxoid L13) 15.0
    pH value is about 5.4, and cultured at 20 ° C for 10 days. The ripened agar is then coated with a 10% glycerol solution (6 ml) and scraped with a sterile instrument in order to loosen spores and mycelium. Aliquots (0.4 ml) obtained
    spore suspensions are transferred to sterile polypropylene straws, which are then thermally sealed and stored in liquid nitrogen vapor until consumed. The contents of a separate straw are used to inoculate 10 ml. Medium A, which is then cultivated at 28 ° C for 3 days on a rocking chair rotating at a speed of 250 rpm with an orbital diameter of 5 50 mm. This cultured medium is used to inoculate (in the amount of 2%) 15 tubes and two Erlenmeyer flasks (capacity 250 ml) containing respectively 10 ml and 50 ml 0 of medium B.
    The tubes and flasks were cultured at 28 ° C for 5 days, and then the cultures were separately filtered under vacuum and the cells were shaken for 30 minutes 5 with methanol, taken in an amount equal to the volume of the culture filtrate.
    Activity against Caenorhabditis elegans is determined in cell extracts grown in test tubes and flasks. 0 Mycelium extracts are combined, evaporated to dryness and re-extracted with methanol to concentrate (6 ml), which is fed to a column filled with H20 seyadex (110 x 2.5 cm) t and eluted with methanol. Collect fractions of 10 ml.
    Fractions 21-28 are grouped and evaporated to form an oily residue (156 kg), which is extracted with a mixture (3: 1) of chloroform: ethyl acetate. 3 ml of extract is obtained, which is subjected to HC (55X X2.5 cm column), 10 ml fractions are collected and analyzed by TLC using plates containing a fluorescent indicator. Fractions 20-23 and 36-44 cause two main areas that quench the fluorescence, they are identified as component 1 (Rf 0.70) and component II (Rf 0.43).
    Upon evaporation of fractions 20-23, component I is obtained in solid form (9 mg). At absorption maxima at 238, 245 and 254 nm, the values of Ep are 340, 350, and 200, respectively.
    Upon evaporation of Fractions 36-44, component II is obtained in solid form (11 mg). At the maxima at 238, 245 and 254 nm, the values of E are respectively 440, 460 and 280.
    Example 2. Each of the two 250 ml Erlenmeyer flasks containing 50 ml of medium L each is inoculated with 0.2 ml of a suspension of spores of Streptomy-ces thermoarchaensis NC1B 12015 taken from straw prepared as described in Example 1. The flasks are cultivated. at 28 ° C for 3 days on a rocking chair rotating at a speed of 250 rpm with an orbital diameter of 50 mm. The contents of both flasks are then used to inoculate a 20 ml vessel-hermenter containing 12 liters of medium B. After 5 days of growth, culture cells are harvested and treated as described in Example 3.
    Example 3. After 5 days of cultivation at 28 ° C. Fermentation broth (12 l), prepared as described in Example 2, collects cells that are centrifuged at a rate of 4200 rpm at 10 ° C for 15 minutes. The pellet from the cells is mixed with 5 liters of methanol and kept at 4 ° C for 20 hours. The mycelial extract is filtered, evaporated at 40 ° C and subjected to azeotropic distillation after adding 100 ml of butanol-1. The extract is then treated with methanol (5 times 200 ml each), the combined extracts are evaporated to a volume of 100 ml and fed to a Sephadex LH20 column (112x5 cm). The column was eluted with methanol and, after a test run of 200 ml, 50 ml of Arations were collected. Fractions 40-90 are grouped and evaporated, yielding 3.85 g of oily residue.
    five
    0
    five
    0
    five
    0
    five
    0
    five
    tatka. This residue is extracted with 77 ml of a mixture (3: 1) of chloroform: ethyl acetate, bilt, and then subjected to separation on HC, and after a test run of 200 ml, fractions of about 15 ml are collected.
    Fractions 124-142, containing component I, are grouped and evaporated to obtain 253 mg of a solid, of which 216 mg are purified by the HPLC method (column with Zorbax ODS, 25k 2.1 cm, elgoent 80% acetonitrile / water). Fractions 250-320, containing component II, are grouped and evaporated to give 602 mg of a solid, of which 540 mg are purified by the HPLC method (as for fractions 124-142) and the Arasions are collected from several runs.
    The material eluted from the HPLC column was monitored by UV spectroscopy at 243 nm. Substances with absorption peaks at this wavelength are dried and tested for activity against Carnorhabditis elegans, and also analyzed by TLC. The four substances that have activity against Caenorhabditis elegans also have a value of Rf 0.39-0.46 or .0.70-0.75.
    Component I gives one peak with Rf value from 0.7 to 0.75, this peak was assigned to factor B. Component II gives three peaks with Rf values of 0.39-0.46, these three peaks were attributed to factors A, C and D.
    Factor A, eluted from the HPLC column between 260 and 340 ml after sample introduction, has a Rf value of 0.44, as determined by TLC. Factor B is eluted from an HPLC column between 270 and 310 ml after the sample has been introduced, and has a Rf value of 0.62, as determined by TLC. Factor C is eluted from an HPLC column between 160 and 180 ml after the sample is introduced, and has a Rf value of 0.4, as determined by TLC. Additional characteristics of factors A, B, C and D are described below.
    Example 4 0.4 ml of a spore suspension of Streptomyces thermoarchaensis NC1B 12015, taken from a straw prepared as described in Example 1, was used to inoculate 50 ml of Medium A contained in a 250 ml Erlenmeyer flask. The flask is cultivated at 28 ° C for 4 days on a rocking chair rotating at a speed of 250 rpm with an orbital diameter
    movement 50 mm. Then, 8 ml dd portions are used to inoculate each of two flat-bottomed flasks containing 400 ml of the same medium, and then cultured under the same conditions for 3 days.
    The contents of both flasks are then used to inoculate a Lermentera vessel with a capacity of 70 liters containing 40 liters of medium B supplemented with silicone 525 (Dow-Horning burma, 0.0625% v / v). Fermentation is carried out with stirring and aeration, which maintains the concentration of dissolved oxygen at a level of more than 20% of saturation, and if necessary, a silicone antifoam is added. After 10 days, fermentation cells are harvested, and the broth (40 L) is clarified by centrifugation (1500 rpm). The supernatant is replaced by water (5 L) and the isolated cells (1.4 kg) are frozen at -20 ° C.
    After a week, the frozen cells are thawed, suspended in 15 liters of methanol and gently stirred for 15 hours. The suspension is then filtered and the solid residue is re-extracted with methanol (10 liters). The combined filters (25 L) are diluted with water (12 L) and extracted with petroleum ether (25 L). After 30 minutes, the Lases are separated by centrifugation.
    The lower methanol phase is again extracted with petroleum ether (3 times: 25, 15 and 15 l). The combined phases of petroleum ether (80 l) are concentrated, passing three times through a pfaudler 8.8-12V-27 thin-film evaporator (vapor pressure 0.1 bar, vapor temperature 20 ° C, water vapor temperature 127 ° C), and concentrate ( 8 l) dried with sodium sulfate (1 kg) and further concentrated under reduced pressure and 40 ° C in a rotary film evaporator. The oily residue (15 ml) was dissolved in a mixture of chloroform and ethyl acetate (70 ml, 3: 1 v / v) and separated into HC, collecting fractions of about 40 ml after a test run of 1400 ml.
    Fractions 45-65 are combined and evaporated, obtaining factor B (940 mg, as indicated in Example 3), which is recrystallized twice from methanol and finally from nitromethane. Crystal0
    five
    0
    they are subjected to single crystal X-ray diffraction analysis, from which it follows that the crystals are orthorhombic transparent prisms with the parameters: a 10,171 / 3 /, b 13,317 / 5 /, с 25,032-7 /, A, cell volume 3391 A3, 2 4, space group P2j2t2i, Dc 1.18 g / cm3, R 0.053 for
    independently observed reflections (0 less than 58), measured by a diffractor with Cu-K radiation (wavelength 1.54178 A).
    Example 5. Strepto-myces thernoarchaensis NC1B 12015 inoculum was prepared as described in Example 4, the growth period was 2 days, and used to inoculate a co-fermentor vessel (70 L) containing 40 L of Medium B, supplemented with polypropylene 2000 (0.065% v / v) instead of silicone 525. Polypropylene 2000 is added as needed during fermentation in order to reduce foaming. Fermentation is carried out at 28 ° C with agitation and aeration, which ensures that the concentration of dissolved oxygen is maintained at more than 30% of saturation. After 24 hours of fermentation, a portion of the broth (1 l) is transferred to a fermenter (700 l) containing 450 l of medium having the following composition, g / l: D-Glucose. 2.8 5 Malt Dextrin
    (M ZOE) 27.8
    Arkazy 5013.9
    Feed syrup1, 7
    KGNR040,14
    0 CACOS 1.39
    Silicone 525 (Dow Cornning), 0.06%
    (v / v)
    The pH is adjusted to 6.5 before sterilization. 5 The fermentation is carried out at 28 ° C with stirring and aeration, ensuring that the concentration of dissolved oxygen is maintained at more than 20% of saturation. After 2 days, the pH was adjusted to 7.2 by adding sulfuric acid. After 5 days of fermentation, culture cells are harvested.
    The broth (450 l) is clarified by centrifugation and the liquid above .. j precipitate is replaced with water (20 l). Selected cells (25.5 kg) are stirred for 1 h in such an amount of methanol that the total volume of the mixture is soy
    75 liters l. The suspension is filtered, the solid residue is re-extracted with 35 L of methanol and filtered. The combined filtrate (87 L) was diluted with water (40 L) and extracted with petroleum ether. After 30 minutes, the phases are separated by centrifugation, and the lower methanol phase is re-extracted with petroleum ether (30 L) after adding 40 L of water. Under separation of the lower phase, 30 liters of PE are extracted again. The combined phases of petroleum ether (85 l) are concentrated, passing 3 times through a pfaudler 8.8-12V-27 thin-film evaporator (vapor pressure 0.1 bar, vapor temperature 20 ° C, water vapor temperature L 127 ° C). The concentrate (9 L) is dried with sodium sulfate (2 kg) and further concentrated under reduced pressure at 40 ° C. in a rotary film evaporator. The oily residue (130 g) was dissolved in chloroform to obtain 190 ml of a mixture, which was subjected to separation into a HC (packed column, washed with 500 ml of chloroform), fractions of about 40 ml were collected after a test run of 1400 ml.
    Fractions 32-46 are combined and evaporated, yielding 21.2 g of oil. Fractions 47-93 are combined and evaporated to give 20.1 g of oil, which is dissolved in a mixture (3: 1) of chloroform: EA to a volume of 50 ml. The solution is divided into HCs, collecting fractions with a volume of about 40 ml after a test run of 1400 ml. Fractions 22-23 are combined and evaporated to give 3.1 g of oil, which is added to the oil obtained from fractions 32-46 on the first column. The combined oils were dissolved in boiling methanol (4 ml), and then this solution was added to 20 ml of hot propanol-2, to form a crystalline Factor B (2.57 g) while holding.
    The mother liquor after crystallization of factor B is evaporated to give an oil, which is dissolved in an equal volume of methylene chloride, and the solution is fed to a column (30x2.2 cm) with merck silica gel 60 (70-230 mesh, ASTM No. 7734) filled in chloride methylene. The layer is washed (twice the volume of the layer) and eluted with a mixture (3: 1) of chloroform: ethyl acetate f (2 layers of the layer). When evaporated. an eluate is obtained an oil which is dissolved in methanol and subjected to preparative separation by HPLC
    five
    0
    five
    Q
    5 0 5
    0 c
    0
    The spursorb S50DS-2 (mm, firm Fatsz Sep. Ltd.). A 5 ml sample is calcined through the column for 1 min and the column is elongated with a mixture (7: 3) of acetonitrile water under the following conditions:
    Time, min Flow, ml / min 0,000.00 (Time
    1,000,00 input
    1,1030,00 samples)
    39.9030.00
    40,0035, OH)
    75,0035.00
    The material eluted from the HPLC column was analyzed by UV spectroscopy at 238.im. Upon evaporation of the combined fractions having a peak eluting at 26.3 minutes, Factor E is obtained in solid form. Upon evaporation of the combined fractions having a peak eluted at 36.4 minutes, factor F is obtained in solid form.
    Example 6. A fermentation broth (similar to Example 2) with a yield of culture cells after 117 hours is treated in an autoclave (121 ° C, 1 hour), cooled to room temperature and stirred on a magnetic stirrer, to obtain a homogeneous cell suspension. Two portions of the suspension (2 ml) are centrifuged (acceleration 12,000 g, 2 min, room temperature), the liquid is decanted over the precipitate and the precipitated cells are suspended in 2 ml of water, mixed thoroughly and centrifuged again (12,000 g, 2 min , room temperature). After decantation of the liquid above the precipitate, the cells are washed twice with distilled water (2 ml portions). The washed cells are then thoroughly mixed with water (2 ml) or methanol (2 ml) and kept at room temperature with occasional shaking for 1.5 hours. The suspension is again centrifuged (12,000 g, 2 min. 9 room temperature) and the supernatants serially diluted in water. The cells from the aqueous suspensions are resuspended in water and immediately serially diluted with water. Portions (10 µl) of each of the dilutions are added to a suspension (200 µl) of the nematode Caenorhabditis elegans in a buffer solution containing, g / l: sodium hydrogen phosphate 6, potassium hydrogen phosphate 3} sodium chloride 5J magnesium sulfate 0.25 - and having pH 7D). After 4 h, the suspension of nematodes and holding medium at 28 ° C for
    follow to establish which dilution of the test mixture causes complete inhibition of mobility of more than 98% of the nematodes in the analyzed suspension. It was found that diluting the methanol extract was 1: 5, 1:25, 1: 250 and 1: 500, diluting the cell suspension 1: 5, 1:25, 1: 250, 1: 500 and 1: 1000 and diluting the aqueous extract 1: 2, 1: 4 and 1: 8 cause such nematode inhibition when 10 µl is added to 200 µl of nematode suspensions.
    Example 7. 50 ml of Medium A or Medium B in a 250 ml Erlemeyer flask is inoculated with 0.4 ml of S. thermmoarchaensis MC1B 12015 spore suspension taken from a straw prepared as described in Example 1. Flasks co or A cultivated for 2 days on a rotary rocking chair operating in the mode. 250 rpm with a stroke diameter of 50 mm. Then, portions (8 ml) are taken from each medium to inoculate 2-liter flat-bottomed flasks containing 400 ml of the same medium (A or B, respectively). These flasks are cultivated for 2 days under the same conditions.
    Two 70-liter fermenters are each inoculated with two flasks between A and one 70-liter fermenter is inoculated with two flasks of B medium. Each Leermenter contains 40 liters of C medium. Fermentation is carried out at 34 ° C with stirring and aeration sufficient to maintain a concentration of dissolved oxygen in excess of 30 % of saturation. After about 24 hours of aermentation, the pH of the mixture was adjusted to 7.2 by the addition of an aqueous solution of sulfuric acid. If necessary, an antifoam agent is added - polypropylene glycol 2000. After 5 days, cells are collected which are combined.
    i
    70-liter fermenter, which
    It is also noculated with two flasks containing medium B, containing medium B with the addition of 0.06% silicone 1520. Fermentation is carried out at 28 ° C with stirring and aeration sufficient to maintain the dissolved oxygen concentration at a level of 30% of saturation. If necessary, polypropylene glycol 2000 is added to reduce foaming. After 24 hours, a portion of 9 liters is transferred to the Lermenter.
    five
    0
    five
    700 l bones, containing 450 l of medium C.
    Fermentation is carried out at 34 ° C with stirring and aeration sufficient to maintain the dissolved oxygen concentration at level u above 30% of saturation. Foaming is controlled by adding polypropylene glycol 2000 and after about 24 hours the pH of the medium is adjusted to about 7.2 by adding an aqueous solution of sulfuric acid. After 4 days of fermentation, culture cells are collected, which are combined with the three fermentation products described above.
    The combined cell broths are centrifuged in a Sharpless A816RU centrifuge at a rate of about 120 l / h. The residual supernatant in the centrifuged vessels is replaced with water.
    The isolated cells (11.65 kg) are suspended in 33 liters of methanol using a Silverson mixer. After 60 min, the suspension is filtered through a keeper cloth and the residue is again suspended in 34 L of methanol. After 40 minutes, the suspension is filtered again. The filtrates from the two methanol extractions are combined.
    The combined extracts (53.5 l) are mixed with 27 l of water and 27 l of petrol lane esyr. After stirring for 20 minutes, the two phases are separated into 5 Westfali MEI 1256 centrifuge. The lower aqueous-methanol phase (70 l) is mixed with water (37 l) and petroleum ether (27 l), mixed and separated, as earlier. The interfacial emulsion in a lase of petroleum ether is broken down with acetone (4 L). The lower aqueous-methanol phase (108 l) is then mixed with water (40 l) and petroleum ether (27 l) for the third time, interleaved and separated, as before, and 4 l of acetone is used to divide the interfacial emulsion . The three hexane extracts are then combined.
    The combined petroleum ether extracts (85 l) are concentrated on a thin-film evaporator (vapor pressure 0.15 bar, vapor temperature 26 ° C). The concentrate (3 l) is dried with sodium sulfate (2 kg) and then additionally evaporated under reduced pressure and 40 ° C. The resulting oil (639 g) is dissolved in 300 ml of a mixture of chloroform and ethyl acetate (3: 1, v / v), filtered and the washing liquids (1060 ml) section
    0
    S
    0
    On an HCK (1500 mm, diameter 100 mm), elute at a flow rate of 6 l / h.
    The fractions eluted between 8.8 and 13.1 l were combined and evaporated at low pressure to give 56.3 g of oil; the fractions eluted between 13.1 and 24.6 l were evaporated in the same way to give a light yellow solid. (153.4 g). The first fractions mainly contain factor B, while the last fractions contain a mixture of factors A, B, C and D. Factor B in this last fraction is successively removed by repeating the separation on HC, as described above, twice (last time on fresh silica gel) under similar conditions, except that the flow rate was reduced to 3 l / h.
    The peaks of substances containing factors A, C and D from the second of these columns eluted between 8.8 and 17.6 l, (the residual factor B, which it contains, is separated on the third column, from which Factors A, C and D elui rutots between 14 and 28 L. This final combined eluate is evaporated under reduced pressure, yielding 114 g of solid. Peaks of substances containing Factor B from two columns (7.5-8.8 l and 10.3- 13.4 L, respectively) is evaporated to an oil (10.7 and 10 g, respectively) and combined with the oil obtained on the first of these three columns.
    The oils containing factor B are grown in boiling methanol (25 ml) and mixed with boiling propanol-2. (100 ml). When cooled to factor B crystallizes. The crystals are filtered, washed with methanol (200 ml), cooled to -20 ° C and dried in vacuo to give 25.3 g of Factor B.
    The solid from the third silica gel column, in which Factors A, C and D are contained, is dried in a vacuum to constant weight (87 g). Samples (20 g) of this solid were dissolved in 190 ml of methanol and brought to a volume of 230 ml with a mixture (7: 3 by volume) of acetonitrile and water. Then, portions (5 ml) of this solution were separated on a chromatographic column (250 mm, diameter 21.2 mm) with an ODS-2 spheriserum (particles with a diameter of 5 µm), using a mixture of (7: 3) acetonitrile and eluting solvent. and water. The eluent flow rate is maintained at 20 ml / min.
    0
    five
    0
    five
    0
    five
    0
    five
    0
    five
    approximately for 10 s, then it is constantly increased to 34 ml / min over a 22-minute period and this speed is maintained for a further 3 min. Eluted factors are detected at a wavelength of 238 nm. Factor C is eluted between 11.0 and 13.4 minutes. Factor D is between 13.4 and 17.4 minutes and factor A is between 17.4 and 23.0 minutes.
    Factor C containing fractions from each chromatographic separation are combined and evaporated at low pressure to a solid. The fractions containing Factor A are likewise evaporated to a solid. The fractions containing Factor D are also combined and evaporated to give a crude solid (7 g). The latter is redissolved in methanol (65 ml), mixed with aqueous acetonntrile (30% by volume of water) and re-separated by chromatography on a column with an ODS-2 spherisorb, as described above, with the exception that the separation is kept constant eluent flow rate of 20 ml / min. Now, ftoror D is eluted between the 16th and the 20th minute, and these fractions from each chromatographic separation are combined. The combined solvents are evaporated to a solid. Three solids, factors A, C and D, are dried over P20d-in vacuum to constant weight (55, 7.0 and 1.21 g, respectively).
    It is shown that each of the four solids isolated in this method is similar to the samples of factors A, B, C, and D.
    Example 8. 50 ml of Medium B, contained in 250 ml Erlenmeyer flasks, are inoculated with a suspension of spores of organisms of Streptomyces thermo arhenensis NC1B 12111, 12112, 12113 and 12114 (0.5 ml each) taken from straws prepared as described in example 1.
    I
    Flasks containing S.thermoarhaensis NC1B 12111, NC1B 13112 and NC1B 12113 are cultured at 31 ° C on a rotary shaker. The flask containing S.thernoarhaensis 12114 is cultivated at 28 ° C for 2 days and then 1 ml of broth is transferred to another Erlenmeyer flask containing 50 ml of medium B. This flask is cultivated at 31 ° C on a rotary shaker. All flasks
    271
    wave at a speed of 250 rpm with a stroke diameter of 50 mm.
    After 4 days of cultivation, centrifuge 10 ml of a sample of each broth at an acceleration of 1250 g for 45 minutes and process as follows. The supernatant is discharged and the pellet is resuspended in 10 ml of methanol. The suspension is thoroughly shaken and kept for 1 hour with occasional stirring. Then the suspension is centrifuged at 10,000 g for 5 min and the supernatant is analyzed by the method HHVR (column S5 ODS-2, 10 cm, diameter 4.6 mm, eluent 70% acetonitrile / / 0.1 and ammonium dihydrophosphate solution) . Geek substances were analyzed at 246 nm.
    In each case, HPLC analysis showed the presence of Lactors A, B, C, and D.
    Example 9. It was established that factors A, B, C, D, E and F contain only carbon, hydrogen and oxygen.
    The electron impact mass spectroscopy (MSED) method was obtained
    H / Z635 (M + Na) M / Z613 (M + H) M / Z691 (M + H + glycerol) M / Z599 (M + NU M / Z581 (MH-PeO) 4 M / Z563 (mi-2K20) four
    M / Z607 (M + Na) {M / Z621 (M + Na) f
    Field desorption mass spectroscopy for Factor E yielded the following results: M / Z 61211, and for Factor F, M / Z 626M4.
    In the spectrum of MSEU factor A, with accurate mass measurements, the following ions are noted: at 612.37 - C36HS208-, 466.31 - С 0Н4г04; 448.30 - SEON400- ,, 425.23 - 354.22 - C2- $ 1CaOg; 297.22 - C2, Hg90; 278.11-C, 247.17 - C, 6H2302; 219.18 - C, 5H2% 0, 95.05 - C6H70.
    In the spectrum of the MSEU factor B, when the masses are accurately determined, the following ions are noted: at 598.35 - Cr5-H5008 438.28 - C2b BL80420.26 - 314.19 - CbrbO; 248.14 - C15-PgoOe; 151.08 - „02.
    28
    results for Factors A, B, C, D, E and F (shown in Table 1).
    Table 1
    The method of mass spectroscopy with fast atom bombardment (MS-FAB) yielded the results given by
    in tab. 2. t table 2
    M / Z61KM-H) 612
    598
    M / Z583 (M-H) 584 M / Z597 (M-H) 598
    In the spectrum of the NSEU factor C, with accurate mass determination, the following ions were noted: at 584.34 - C34H4808; 566.33 438.28 - C28H38Of.
    In the spectrum of the NSEU of the D factor, when accurately determining the masses, the following ions were noted: 1RI 598.35-Cr5. H5008; 452.29-Cr9H 1 (p4,434.28 - C29H3803.
    In the spectrum of the MSEU of factor E, when the masses are accurately determined, the ions are marked: at 452.2908 -., And for factor F, the ions at 466.3067 - C 0H4gCF Factors A, B, C, D, EuP have the following characteristic peaks tre (in bromoLorm).
    29,
    The dll of Lactor A is about 3510 (OH), 1712 (complex air) and 998 (C-0). For bactor B about 3510 (OH),
    1710 (ester) and 996 cm ((C-0). For Lactor C about 3510 (OH)
    1712 (complex) and 996 cm- (C-O). For Factor D about 3508 (OH) “,
    1711 (complex eLir) and 996 (C-0). For Lactor E, about 3,500 (OH);
    1708 (ester) and 994 cm (C-0).
    For factor F, about 3100 (OH); 1708 (ester) and 997 cm (C-0).
    The factors A, B, C, D, E and F have UV spectra in methanol solution (0.002%), where P is the bend and M is the maximum (see Table 3).
    Table 3
     Concentration in methanol, 001%
    The given high values of D waKC are the characteristic of each factor, the values of E (reflecting the purity of the material as obtained (the ratios of the value of E are characteristic for the majority).
    Proton Magnetic Resonance Spectra (PNR) at 200 MHz each
    ten
    25
    3809030
    factors in deuterochloroform solution include the following signals (values of 1 with multiplicity, combination constants (Hz) and integral values in brackets).
    Factor A: 4.1-4.4 (m, 2H), 4.61 (broad s, 1H) j 4.6-4.75 (m, 2H), 4.81 (d, 9, 110 i 5.05 (m, 1H) 5.34 (s, 2H) J 5.69 (d, 5, 1H) 6.06 (d, 5, 1H) 6.17 (m, 1H) {6.26 ( d, 11, 1H) {6.37 (m, 1H); 6.46 (d, 10, 1H) "6.74 (k, 2, 1H); 7.42 (m, 1H) Jf 7.7 -7.9 (m, 5H) {8.14 (s, ZN) 8.40 (s, ZN); 8.47 (s,., ZN) 8.61 (t, 11, 1H) J 8, 96 (d, 7, J AH)} 9.06 (d, 7, 3H) J 9.02 (d, 7, H),
    9.13 (q, 11, 1H); 9.21 (d, 7 MN). Factor B: 4.2-4.4 (m, 2H) 15 4.55
    (c, 7, 111) 4.65 (wide s, 1H), 4.6–20 4.8 (m, 2H), 5.06 (m, 1H) 5.3–5.5 (m, 2H); 6.01 (d, 5, 110, 6.07 (d, 5, PA, 6.12 (s, 1H) 6.24 (d, 11, PO; 6.24 (m, 110 J 6.3 - 6.5 (m, 2H); v 6.53 (s, 3N); 6.73 (k, 2, 1H), 7.62 (m, 1H); 7.6-8.0 (m, 4H ) J 8.22 (s, ZN), 8.35 (d, 7, ZN), 8.41 (s, ZN) J 8.49 (s, ZN), 8.62 (t, I, 1H) ; 9.03 (d, 6, ЗН), 9.12 (к, 11, 1Н) - 9.22 (d, ЗН).
    Factor C: 4.29 (d, 11, t, 2, 1H), 4.4–4.6 (m, 3N) {4.56 (broad s, 110, 5 .14 (dd, 15, 10 , 1H)} 5.23 (m, 111), 5; b5 (shir, s, 2H); 5.72 (d, 6, 111) J 5.95 (d, 10, 1H), 5.99 ( d, 6, 1И) f 6.08 (sch. s, 1H) 6.1-6.4 (m, 310 /
    35 6.62 (q, 3, 1H); 7.7-8.1 (m, about 1H) J 7.18 (s, 3H) J 8.33 (s, ZN) / 8.48 (d, 1, ZN) 8.64 (s, ZN) , 8.68 (t, 11, 1H); 9.00 (d, 7), 9.08 (d, 7, AH) f 9.12 (k, 12, PO.
    40 Factor D: 4.18-414 (m, 2H)} 4.47- 4.82 (m, 4H); 5.04 (m, 1H) / 5 „35 (s, 2H); 5.72 (d, 7, 1H) J 6.07 (d, 7, 1H) 6.15-6.45 (m, 4H); 6.74 (q, 4, 1H), 7.45-8.1 (m, 8H); 8.16 (s, 3N); 8.41
    45 (s, 3N), 8.49 (s, 3N) J 8.62 (t, 11, 1H); 8.92-9.05 (m, 6H) 9S21 (d, 7, 3N).
    Es 491-493 (m, 21), 4.5-4.8 (m, 4H total)} 5.04 (m, 1H); 5.2-5.5
    50 (m, 2H); 6.01 (d, 5, 1H), 6.05 (d, 5, 1H) J 6.11 (s, 1H); 6.1-6.4 (m, 3N) / 6.45 (d, PO 6.51 (s, 3N) {6.70 (q, 2, 1H); 7.60 (m, 1H) {8 , 20 (s, 3H) J 8.41 (s, 3N) 8.47 (s, 3N), 8.60 (t,
    55 11, 1H) "9.00 (t, 7, 3H) f 9.02 (d
    6, 3N) 9.11 (q, 11, 1H), 9.20 (d
    7, ZN).
    Factor F: 4.2-4.4 (m, 2H), 4.62 (s, in), about 4.70 (m, 2H); 4.80 (d,
    thirty
    15
    20
    31
    , 1H) "5.04 (m, 1H) J 5.2-5.5 (m, 2H), 99 (d, 5, 1H); 6.05 (d, 5, 1H); , 11 (s, 1H) J 6.1–6.3 (m, 2H), about, 36 (m, 111); 6.45 (d, 10, 1H) 6.51 (s, 3N), 6.70 (q, 2, 1H); 7.42 (m, 1H); 7.58 (m, BUT} 8.19 (s, ZN) G 8.40 (s, ZN), 8.47 (s, ZN) 8.60 (t, 11, 1IOJ 8.95 (d, ZN ); 9.05 (d, 7, ZN), 9.01 (d, 7, ZN), 9.10 (k, 11, 1H), 9.21 (d, 6, ZN).
    Noise-filtered spectrum
    | 0L
    NMR-C at 25.05 11 Hz of a solution of each oactor in deuterochloroform includes peaks (values in brackets for the multiplicity of signals from the extraresonance spectrum).
    Factor A at 173; 2 (s) 142.6 (d);
    139.2 (s); 137.6 (s) {137.1 (s) /
    137.0 (d) - 130.4 (s); 123.1 (d)
    120.1 (d); 171.8 (d), 99.5 (s),
    80.0 (s); 79.0 (d) 76.5 (d); 69.0 (d), 68, 67.4 (d); 48.2 (t), 45.4 (d), 40.9 (t) 40.5 (t)} 35, 34.5 (t) 22.1 (k) {34.5 (t) 26, 6 (e)}
    22.6 (к), 22.0 (к) $ 19.7 (к) 15.3 (к) “13.7 (к); 10.8 (k).
    Factor B at 173.4 (c) j 142.1 (d); 139.5 (s) 137.1 (s); 136.7 (s) / 133.7 (s); 123.6 (d); 123.3 (d), 120.0 (d); 119.3 (d) 118.2 (d)} 99.5 (s) 80.1 (s), 77.3 (d); 76.6 (d) 76.4 (d); 69.0 (d); 68.3 (d); 67.9 67, 57.5 (k); 1 48.2 (“) 45.4 (d);
    40.7 (t) 40.5 (t) 35, 34.5 (t);
    22.1 (k); 19.6 (k); 15.3 (q); 13.6 (k) 35 12.9 (k); 10.5 (k).
    Lactor C at: 173.3 (s)} 142.2 (d);
    140.3 (s); 138.5 (s) 137 (s) 134.9 (s); 123.9 (d); 121.1 (d) 120.6 (d), 118.1 (d); 100.2 (s) $ 80.6 (s), 80.1 (d), 77.4 (d); 69.2 (d), 69.0 (d) 68, 68.0 (d) {67.9 (d); 48.6 (t) for 46.3 (d)} 41.4 (t); 36, 36.3, 36.1 (d) 1, 35.0 (t); 22.6 (q), 20.0 (q)}
    15.4 (k); 14.3 (k), 13.1 (k); 10.8 (k).
    25
    17380
    .Q
    4S
    thirty
    40
    Factor D at: 173.2 (s), 142.5 (d)
     139.1 (s); 137.5 (s); 137.1 (s); 132.1 (s); 131.4 (d); 123.1 (d) 120.1 (d); 117.8 (d) -, 99.5 (s); 79.9 (s); 79.2 (d); 76.5 (d) J 69.0 (d), 68.3, 68, 67, 67.4, 48.2 (t); 45.5 (d); 40.8 (t); 40.5 (t) / 35, 34.5 (t); 22.0 (k) 20.6 (t), 19.6 (k); 15.3 (q); 13.7 (k); 13.6 (k); 10.7 (k).
    Circular dichronism curves for Aaktor A, B, C, and D (concentration
    15
    20

     35
    ;
    }
    25

    73809032
    solutions in methanol (about 0.1%) are poorly resolved in the region of 230-260, which is associated with the absorption of a diene chromophore. This indicates that in all four factors, the absolute configurations for carbon atoms are Co, C 7 C and are the same.
    The following are examples of formulations according to the invention (the active ingredient is the substance obtained by the proposed method, which may be one of the factors A, B, C, D, E or F.
    Parenteral multi-dose injection (range 1–5 wt./vol.%):
    Active ingredient 4.0 Benzyl alcohol 2.0 Glycerin triacetate 30.0 Propylene glycol Up to 100.0 The active ingredient is dissolved in benzyl alcohol and glycerin triacetate. Propylene glycol is added and made up to volume. The solution is filtered to remove any solids. The product is aseptically filled into injection vials and sealed with rubber seals or pistons held in place by aluminum caps. The product is finally sterilized by heating in an autoclave.
    Aerosol dispenser (range 0.01-0.50 wt.%), Wt./weightL: Active ingredient 0.1 Trichloroethane29.9
    Trichlorobormetan 35.0 Dichlorofluoromethane 35.0 The active ingredient is mixed with trichloroethane and filled into an aerosol container. Purge the head space with a gas spray and compress the valve in place. Under pressure, the required amount of 4S liquid sprayer is introduced through the valve. Install starter and inner cover.
    Pills. Way
    production - wet mg 50 granulation: wt.%
    Active ingredient 250.0 Magnesium stearate 1 4.5 Corn starch 5 22.5 Sodium glycol t-55 mala2 9.0
    Sodium lauryl sulfate 1 4.5
    thirty
    40
    Microcrystalline cellulose - for the shell of a tablet weighing 450 mg.
    A sufficient amount of 10% starch paste is added to the active ingredient to make a wet mass convenient for granulation. The granules are molded and dried using a drying tray or dryer in a baking layer. Sift through a sieve, add remaining components and compress into tablets.
    If necessary, the surface of the tablet is covered with a film using oxnimethylcellulose or another similar film-forming material, using an aqueous or non-aqueous solvent system. Plasticizer and a suitable paint can be included in the coating film.
    Veterinary tablet for small pets. Production method — dry granulation. Composition mg: Active ingredient 50.0 Magnesium stearate 7.5 Microcrystalline cellulose for tablet shell 75.0
    The active ingredient is mixed with magnesium stearate and microcrystalline cellulose, and worms are made from the mixture. Crush the worms, pass them through the rotary granulator, get free flowing tablets. Pressed into tablets. The shell of the tablets can then be covered with a film.
    Veterinary intrathoracic injection:
    Active ingredient, mg 150 Polysorbate 60, wt.% Up to 3.0 White beeswax, wt.% 6.0
    Peanut butter, wt.% 91 Heat peanut shear, white beeswax and polysorbate 60 to. 160 ° C with stirring. It is kept for 2 hours at this temperature and then cooled to room temperature with stirring.
    Aseptically add the active ingredient to the carrier and disperse using a high speed blender. Purified by passing through a colloid mill. Aseptically fill the product into sterile plastic syringes.
    Veterinary oral alcohol, wt / vol.%:
    Active ingredient 0.35 Polysorbate 85 5.0 - Benzyl alcohol 3.0 Propylene glycol 30.0
    ABOUT
    five
    0
    five
    0
    five
    0
    five
    0
    five
    Yosbatny buoyer to pH 6.0-6.5 Water Up to 100.0
    The active ingredient is dissolved in polysorbate 85, benzyl alcohol and propylene glycol. A portion of the water is added and the pH is adjusted to 6.0-6.5 with phosphate buffer (if necessary). Add the remaining amount of water. Fill the product into the capacity of the solvent.
    Veterinary oral paste, wt.%:
    Active ingredient 7.5 Saccharin25, O
    Polysorbate 85 3.0 Aluminum distearate 5.0 Fractionated coconut oil Up to 100.0 | Aluminum distearate is dispersed in fractionated coconut oil and polysorbate 85 by heating. The mixture is cooled to room temperature and the saccharin is dispersed in an oil vehicle. Distribute the active component at the base. Fill with plastic syringes.
    Granules for veterinary prescription for food, wt.%:
    Active ingredient 2.5 Lime flour To 100.0 Mix the active ingredient with lime flour. The granules are molded using a wet granulation method. Dry using a drying tray or dryer in a fluidized bed. Fill into suitable containers. Emulsifiable concentrate Active ingredient, g 50 Anionic emulsifier (for example, phenylsulfate CALX), g 40 Non-genic emulsifier (for example, Siperonik NP 13), g 60 Aromatic solvent (for example, Solvesso 100), l To 1 All components are mixed and stir until dissolved. Granules, g:
    a) Active ingredient 50 Wood resin 40 Gypsum granules, 20-60 mesh (for example, Agsorb 100 A) Up to 1000
    b) Active ingredient 50 Siperonic NP 13 40 Gypsum granules
    (20-60 mesh) Up to 1000
    ; 351738090
    All components are dissolved in a volatile solvent, for example, methylene chloride, added to the granules, treated in a mixer drum. Dry to remove the solvent.
    The activity of factors L, B, C, D, E and F is determined using a variety of pests and their hosts, including the following: Tetranyc husurticae (ordinary beans and Mirabelle B), Myzus persicae (Chinese and radish drops), Heliotlus virescens (cotton ), Chilo-portellus (Faro Reypa), Meloidogyne
    36
    CH3N
    .Q where Rj is isopropyl or methyl,
    ethyl;
    Rg is hydrogen or methyl, which consists in the anaerobic culture of the strains Stpertomyces th
    incop, nita (golden bean), Panon-archaensis NC1B 12015, or NC1B
    , / "T. 1JU .. 3
    chus ulmi (Mirabelle B), Phorodon hu-muli (hops), Aulacorthus circurafle-xutn (cyclamen).
    The product is used as a liquid preparation (for example, a solution in acetone). These solutions are then diluted with water containing 0.1 or 0.01 wt.% Of a moisturizing agent, until the liquid preparations contain the desired product concentration.
    The test method adopted for each pest involves placing several pests on the medium, which is usually the host plant, and this medium is treated with the preparation (residual test). In the case of Tetranyc urticae, the preparation is treated with both pests and medium (contact test).
    Using this technique, A-F factors are found to be effective at concentrations (by weight of the product) of up to 500 ppm or less.
    权利要求:
    Claims (6)
    [1]
    1. The method of obtaining the antibiotic S 54-j formula
    12111, or NC1B 12112, or NC1B 12113, or NC1B 12114 on a liquid solid medium containing source of carbon, bunker and mineral with 20 at 28-34 ° 0 at pH 5.4-7.2 for 5-10 days, followed by isolating the left compound by extraction with a water-soluble solvent.
    [2]
    2. The Streptomycete Stretch 2 $ ees thermoarchaensis NC1B 12112
    antibiotic producer S 541
    [3]
    3. Streptomyces Strep ces thermoarchaensis NC1B 12015 Antibiotic Producer
    [4]
    y 4. The strain of Streptomycete Strept ces thermoarchaensis NC1B 12111 producing antibiotic
    [5]
    5. Itamm streptomycete Strept ces thermoarchaensis NC1B 12113 producing antibiotic K
    [6]
    6. Strain Streptomycete Strept ces thermoarchaensis NC1B 12114 producing antibiotic S54 (
    The priority is in points and recognized on 09/14/84 of claim 1 of the antibiotic S 0 strain 12015, which has features that characterize the conditions of the method;
    12.21.84 p.Z /
    36
    CH3N
    where Rj is isopropyl or methyl, or
    ethyl;(
    Rg is hydrogen or methyl, consisting in the anaerobic cultivation of strains of Stpertomyces thermoarchaensis NC1B 12015, or NC1B
    12111, or NC1B 12112, or NC1B 12113, or NC1B 12114 on a liquid nutrient medium containing carbon sources, bunker and mineral salts, at 28-34 ° 0 at pH 5.4-7.2 for 5-10 days, followed by isolating the title compound by extraction with a water-soluble solvent.
    2. The strain of Streptomycete Streptomy-ees thermoarchaensis NC1B 12112 producing antibiotic S 541
    3. Streptomyces Streptomy-ces thermoarchaensis NC1B 12015 Strain - antibiotic producer
    4. Strain Streptomycete Streptomy-ces thermoarchaensis NC1B 12111 - antibiotic producer
    5. Itamm Streptomycete Streptomy-ces thermoarchaensis NC1B 12113 - antibiotic producer 6. Strain Streptomycete Streptomy-ces thermoarchaensis NC1B 12114 - Producer antibiotic S54 (
    Priority points and features: 14.09.84 according to claim 1, the antibiotic S y, strain 12015, has signs that characterize the conditions of the method;
    12.21.84 p.Z /
    13.09.85po paragraph 1, 2, 4-6.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1738090A3|1992-05-30|Method for preparation of antibiotic @@@ and streptomycetes strains-producers of antibiotic @@@
    EP0170006B1|1992-07-08|Method and compositions for helmintic, arthropod ectoparasitic and acaridal infections with novel agents
    JP4258575B2|2009-04-30|Novel A83543 compounds and methods for their production
    HU221276B1|2002-09-28|Polycyclic antiparasitic agents, process and strain for their preparation and their use
    US5051255A|1991-09-24|Nematocidal preparations
    EP0573628A1|1993-12-15|New a83543 compounds and process for production thereof
    US5182207A|1993-01-26|Strains of streptomyces thermoarchaensis
    DK168159B1|1994-02-21|Process for the preparation of avermectins and milbemycins related compounds
    DK168866B1|1994-06-27|5-Keto-S541 macrolide compound; crystalline product containing over 90% of the compound; preparations containing the compound for use in human and veterinary medicine; pest control preparation containing the compound; non-therapeutic method for controlling pests using the compound; process for preparing a fermentation medium containing
    EP0050964B1|1987-03-04|Macrocyclic lactones, their production and parasiticidal uses, compositions containing them, and a biological culture suitable for producing them
    RU2029783C1|1995-02-27|Method of antibiotic preparing
    AT398312B|1994-11-25|Process for the preparation of a novel macrolide compound
    RU2100354C1|1997-12-27|Macrocyclic lactone, pharmaceutical composition having antibiotic activity and insect-acaricide composition
    JPH0824593B2|1996-03-13|Antibiotics LL-C23024β and iota
    同族专利:
    公开号 | 公开日
    SE8504254L|1986-03-15|
    BG44205A3|1988-10-14|
    JPH07213278A|1995-08-15|
    IL76385D0|1986-01-31|
    NL8502511A|1986-04-01|
    US4898821A|1990-02-06|
    FI853520L|1986-03-15|
    SE8802985D0|1988-08-25|
    HUT39779A|1986-10-29|
    NZ213463A|1993-04-28|
    DK162099C|1992-02-24|
    IT8548551D0|1985-09-13|
    KR860002576A|1986-04-26|
    UA19162A|1997-12-25|
    IE852263L|1986-03-14|
    DK418085D0|1985-09-13|
    JP2566385B2|1996-12-25|
    BE903232A|1986-03-13|
    IE59394B1|1994-02-23|
    AT396250B|1993-07-26|
    SE502748C2|1995-12-18|
    PT81125B|1987-10-20|
    DK162099B|1991-09-16|
    JPS61118387A|1986-06-05|
    AU4742685A|1986-03-20|
    PH24247A|1990-05-04|
    LU86074A1|1986-04-03|
    SE8504254D0|1985-09-13|
    JPH07116199B2|1995-12-13|
    GR852232B|1986-01-14|
    ES8704545A1|1987-04-01|
    SE8802985L|1988-08-25|
    FI87366B|1992-09-15|
    KR940004098B1|1994-05-13|
    SE469173B|1993-05-24|
    PH21995A|1988-05-02|
    ZW15585A1|1986-04-23|
    CS268803B2|1990-04-11|
    CA1313155C|1993-01-26|
    FR2570390B1|1987-11-27|
    FR2570390A1|1986-03-21|
    ATA268485A|1992-11-15|
    CH666690A5|1988-08-15|
    HU197046B|1989-02-28|
    IL76385A|1990-09-17|
    DK418085A|1986-03-15|
    CS654685A2|1989-08-14|
    BR8504457A|1986-07-15|
    GB2166436A|1986-05-08|
    AU596565B2|1990-05-10|
    GB2166436B|1989-05-24|
    ES8802555A1|1988-08-01|
    US4935531A|1990-06-19|
    PL152148B1|1990-11-30|
    FI853520A0|1985-09-13|
    DE3532794A1|1986-04-17|
    PL255360A1|1988-02-18|
    ES546962A0|1987-04-01|
    RO92478A|1987-09-30|
    FI87366C|1992-12-28|
    ES557237A0|1988-08-01|
    GB8522699D0|1985-10-16|
    PT81125A|1985-10-01|
    IT1182857B|1987-10-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    MD96C2|1984-09-14|1995-03-31|Эмерикэн Сайенэмид Компэни|Method for preparation of the S541 antibiotic, strains of the S541 antibiotic|JPS4914624A|1972-06-08|1974-02-08|
    SE434277B|1976-04-19|1984-07-16|Merck & Co Inc|SET TO MAKE NEW ANTIHELMINTICALLY EFFECTIVE ASSOCIATIONS BY CULTIVATING STREPTOMYCS AVERMITILIS|
    PH16612A|1977-12-19|1983-11-28|Merck & Co Inc|13-halo and 13-deoxy derivatives of c-076 compounds|
    US4171314A|1977-12-19|1979-10-16|Merck & Co., Inc.|13-Halo and 13-deoxy C-076 compounds|
    US4173571A|1977-12-19|1979-11-06|Merck & Co., Inc.|13-Halo and 13-deoxy derivatives of C-076 compounds|
    US4200581A|1978-08-04|1980-04-29|Merck & Co., Inc.|Alkyl derivatives of C-076 compounds|
    NZ201681A|1981-09-03|1985-11-08|Merck & Co Inc|Avermectin derivatives and parasiticidal compositions|
    EP0170006B1|1984-06-05|1992-07-08|American Cyanamid Company|Method and compositions for helmintic, arthropod ectoparasitic and acaridal infections with novel agents|
    IL78621A|1985-04-30|1991-06-30|American Cyanamid Co|Mylbemycin analogs,their preparation and pesticidal compositions containing them|
    ES8800986A1|1985-07-27|1987-12-01|Pfizer|Antiparasitic avermectin and milbemycin derivatives and process for their preparation.|US4696922A|1984-11-26|1987-09-29|Ciba-Geigy Corporation|5-azolylacetoxymilbemycins as ecto- and endoparasites|
    IL78621A|1985-04-30|1991-06-30|American Cyanamid Co|Mylbemycin analogs,their preparation and pesticidal compositions containing them|
    AT399441B|1985-04-30|1995-05-26|American Cyanamid Co|Pesticide and method of controlling pests|
    ES8800986A1|1985-07-27|1987-12-01|Pfizer|Antiparasitic avermectin and milbemycin derivatives and process for their preparation.|
    US5840704A|1986-07-16|1998-11-24|Pfizer Inc.|Antiparasitic agents and process for their preparation|
    AU598204B2|1985-09-13|1990-06-21|American Cyanamid Company|Chemical derivatives of antibiotics S541|
    GR870397B|1986-03-12|1987-07-10|Glaxo Group Ltd|Macrolide compounds|
    GB8606105D0|1986-03-12|1986-04-16|Glaxo Group Ltd|Chemical compounds|
    GB8606116D0|1986-03-12|1986-04-16|Glaxo Group Ltd|Process|
    EP0238259B1|1986-03-12|1993-09-29|American Cyanamid Company|Macrolide compounds|
    AT398312B|1986-03-12|1994-11-25|American Cyanamid Co|Process for the preparation of a novel macrolide compound|
    GB8606120D0|1986-03-12|1986-04-16|Glaxo Group Ltd|Process|
    GB8613790D0|1986-06-06|1986-07-09|Glaxo Group Ltd|Chemical compounds|
    CA1296329C|1986-06-06|1992-02-25|Derek R. Sutherland|Macrolide compounds|
    NZ221077A|1986-07-18|1990-06-26|Ciba Geigy Ag|13b-alkyl milbemycins and use as parasiticides|
    JP2587241B2|1986-07-24|1997-03-05|ビ−チヤム・グル−プ・ピ−エルシ−|Novel compound, production method thereof and pharmaceutical composition containing the same|
    US5149832A|1986-09-12|1992-09-22|American Cyanamid Company|Mono and diacyl derivatives of ll-f28249 compounds|
    US4886828A|1986-09-12|1989-12-12|American Cyanamid Company|Δ22 -derivatives of LL-F28249 compounds|
    DE3750355T2|1986-09-12|1995-04-06|American Cyanamid Co|23-Oxoand 23-imino derivatives of LL-F28249 compounds.|
    US5019589A|1986-09-12|1991-05-28|American Cyanamid Company|Δ23 -LL-F28249 compounds|
    ES2055695T3|1986-09-12|1994-09-01|American Cyanamid Co|DERIVATIVES 23-DESOXY OF COMPOUNDS LL-F28249.|
    US4916154A|1986-09-12|1990-04-10|American Cyanamid Company|23-Imino derivatives of LL-F28249 compounds|
    US5525506A|1987-01-23|1996-06-11|Pfizer Inc.|Process for production of avermectins and cultures therefor|
    US5234831A|1987-01-23|1993-08-10|Pfizer Inc|Cultures for production of B avermectins|
    US5238848A|1987-01-23|1993-08-24|Pfizer Inc|Cultures for production of avermectins|
    US5183749A|1987-02-04|1993-02-02|Sankyo Company, Ltd.|Microbial process for the preparation of milbemycin derivatives|
    US4897416A|1987-02-18|1990-01-30|Ciba-Geigy Corporation|Insecticides and parasiticides|
    US4851428A|1987-03-06|1989-07-25|American Cyanamid Company|Mono- and diepoxide derivatives of Δ22-LL-F28249 compounds|
    US4876272A|1987-03-06|1989-10-24|American Cyanamid Company|Mono- and diepoxide derivatives of LL-F28249 compounds|
    US4886830A|1987-03-06|1989-12-12|American Cyanamid Company|Mono- and diepoxide derivatives of 23-deoxyl-LL-F28249 compounds|
    US4855317A|1987-03-06|1989-08-08|Ciba-Geigy Corporation|Insecticides and parasiticides|
    US4956479A|1987-03-06|1990-09-11|American Cyanamid Company|23-deoxy-27-chloro derivatives of LL-F28249 compounds|
    US4886829A|1987-03-06|1989-12-12|American Cyanamid Company|23-Oxoand 23-imino derivatives of mono- and diepoxy LL-F28249 compounds|
    US4806527A|1987-03-16|1989-02-21|Merck & Co., Inc.|Avermectin derivatives|
    US4871719A|1987-03-24|1989-10-03|Ciba-Geigy Corporation|Composition for controlling parasites in productive livestock|
    EP0285561A3|1987-03-27|1989-10-25|Ciba-Geigy Ag|Milbemycin derivatives with a paraciticidal and insecticidal activity|
    GB8721377D0|1987-09-11|1987-10-21|Glaxo Group Ltd|Chemical compounds|
    GB8721378D0|1987-09-11|1987-10-21|Glaxo Group Ltd|Chemical process|
    GB8721375D0|1987-09-11|1987-10-21|Glaxo Group Ltd|Chemical process|
    GB8721647D0|1987-09-15|1987-10-21|Pfizer Ltd|Antiparasitic agents|
    US5240850A|1987-10-23|1993-08-31|Pfizer Inc.|Cultures for production of avermectin aglycones|
    CA1340771C|1987-11-09|1999-09-28|Shih-Jen Edward Lee|Ethylated avermectins|
    GB8726730D0|1987-11-14|1987-12-16|Pfizer Ltd|Antiparasitic agents|
    GB8803836D0|1988-02-18|1988-03-16|Glaxo Group Ltd|Compositions|
    GB8804440D0|1988-02-25|1988-03-23|Pfizer Ltd|Antiparasitic agents|
    GB8805978D0|1988-03-14|1988-04-13|Glaxo Group Ltd|Process|
    GB8813760D0|1988-06-10|1988-07-13|American Cyanamid Co|Chemical process|
    NZ232422A|1989-02-16|1992-11-25|Merck & Co Inc|13-ketal milbemycin derivatives and parasiticides|
    US5322692A|1989-02-28|1994-06-21|American Cyanamid Company|Sustained release bolus effective for the prolonged prevention, treatment or control of nematode, acarid and endo- and ectoparasitic infestations of ruminants|
    EP0393890B1|1989-04-11|1992-08-12|Pfizer Limited|Injectable compositions containing 25-cyclohexyl-avermectin b1|
    US6001822A|1989-04-11|1999-12-14|Pfizer Inc.|Antiparasitic formulations|
    DK0426948T3|1989-08-11|1996-05-28|American Cyanamid Co|Aryl pyrrols such as insecticidal, acaricidal and nematodicidal agents as well as methods for their preparation|
    NZ234802A|1989-08-14|1992-11-25|Merck & Co Inc|Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals|
    US5830875A|1989-10-30|1998-11-03|Merck & Co., Inc.|24-and 25-substituted avermectin and milbemycin derivatives|
    US5055454A|1989-10-30|1991-10-08|Merck & Co., Inc.|13-epi-avermectin derivatives useful as antiparasitic agents|
    US5208222A|1991-03-28|1993-05-04|Merck & Co., Inc.|4"-and 4'-alkylthio avermectin derivatives|
    US5262400A|1991-06-20|1993-11-16|Merck & Co., Inc.|4α-substituted avermectin derivatives|
    MD24C2|1991-07-09|1994-05-31|Fabrica De Parfumerii Si Cosmetica "Viorica"|Composition of odoriderous substances|
    GB9205007D0|1992-03-07|1992-04-22|Pfizer Ltd|Antiparasitic agents|
    US5229415A|1992-03-24|1993-07-20|Merck & Co., Inc.|Alkylthio alkyl avermectins are active antiparasitic agents|
    US6103504A|1992-03-25|2000-08-15|Pfizer Inc.|Process for production of avermectins and cultures therefor|
    US6486195B1|1993-08-19|2002-11-26|Merck & Co., Inc.|Thermodynamically stable crystal form of 4″-deoxy-4″-epi-methylamino avermectin B1a/B1b benzoic acid salt and processes for its preparation|
    JP2855181B2|1993-12-10|1999-02-10|敏雄 鈴木|Composition and method for preventing pine wilt|
    AU9785698A|1997-10-02|1999-04-27|Microcide Pharmaceuticals, Inc.|Fungal efflux pump inhibitors|
    DE60118132T2|2000-10-10|2006-10-19|Wyeth|anthelmintics|
    GB0205253D0|2002-03-06|2002-04-17|Univ Gent|Immediate release pharmaceutical granule compositions and a continuous process for making them|
    KR100617648B1|2005-02-25|2006-09-05|김응권|Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum|
    CN100394983C|2006-01-09|2008-06-18|浙江海正药业股份有限公司|Doramectin injection fluid containing soyban oil|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    GB848423278A|GB8423278D0|1984-09-14|1984-09-14|Antibiotic compounds|
    GB848432519A|GB8432519D0|1984-12-21|1984-12-21|Antibiotic compounds|LTRP1261A| LT2644B|1984-09-14|1993-09-29|ANTIBIOTIC S541 RECEIVING BUDGET FOR STREPTOMICETAS STAMAI-ANTIBIOTIC S541 PRODUCER|
    LV931143A| LV5536A3|1984-09-14|1993-10-08|Pan-sink for s-541 antibiotic s-541 streptomycete strain-antibiotic producers|
    MD94-0128A| MD96C2|1984-09-14|1994-05-06|Method for preparation of the S541 antibiotic, strains of the S541 antibiotic|
    [返回顶部]